On Monday the FDA required all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, Zepbound, and Soliqua, to warn of NAION, a rare condition that can cause sudden painless vision loss and permanent blindness. The step follows a 2024 JAMA Ophthalmology study linking GLP-1 use to higher NAION risk; ther